Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Level BiotechnologyROCO:3118 76 EBITDA Margin % is 15.26% as of Dec. 2025, which is 0% above its 10-year median of 15.23. GuruFocus rates ROCO:3118 with a GF Score™ of 76/100 and a GF Value™ of NT$35.57 (Modestly Undervalued). The stock has 2 warning signs investors should review. Among 940 Biotechnology companies, Level Biotechnology ranks better than 79.47% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Level Biotechnology's EBITDA for the
three
months ended in Dec. 2025 was NT$28.7 Mil. Level Biotechnology's Revenue for the
three
months ended in Dec. 2025 was NT$188.0 Mil. Therefore, Level Biotechnology's EBITDA margin for the quarter that ended in Dec. 2025 was 15.26%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Level Biotechnology EBITDA Margin % Related Terms
Level Biotechnology EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Level Biotechnology's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:3118 vs VRTX, REGN, ALNY: EBITDA Margin % Comparison
For the Biotechnology subindustry, Level Biotechnology's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Level Biotechnology EBITDA Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Level Biotechnology's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Level Biotechnology's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Level Biotechnology (ROCO:3118) has a EBITDA Margin % of 15.26% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Level Biotechnology and its competitors. This is near median its historical median of 15.23. Over the past decade, Level Biotechnology's EBITDA Margin % has ranged from 10.44 to 17.20. According to the industry distribution chart, Level Biotechnology ranks #193 out of 940 companies in the Biotechnology industry, placing it in the top 20.5%.
Is Level Biotechnology's EBITDA Margin % too high?
Level Biotechnology's current EBITDA Margin % of 15.26% is near median its 10-year median of 15.23. Over the past 10 years, this metric has ranged from a low of 10.44 to a high of 17.20. Based on the distribution chart, Level Biotechnology ranks #193 out of 940 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Level Biotechnology has a GF Score™ of 76/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Level Biotechnology's EBITDA Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Level Biotechnology ranks #193 out of 940 companies for EBITDA Margin %. This places Level Biotechnology in the top 21% of its industry — outperforming the majority of peers. Historically, Level Biotechnology's own EBITDA Margin % has ranged from 10.44 to 17.20 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Level Biotechnology and its competitors. Level Biotechnology's current EBITDA Margin % is 15.26%, which is near median its own 10-year median of 15.23. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Level Biotechnology stock overvalued right now?
Based on GuruFocus' analysis, Level Biotechnology (ROCO:3118) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$35.57, compared to a current price of NT$31.75 — trading 10.7% below its estimated fair value. The current EBITDA Margin % is 15.26%, which is near median its 10-year median of 15.23. Level Biotechnology's overall GF Score™ is 76/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Level Biotechnology (ROCO:3118), the current EBITDA Margin % is 15.26% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Level Biotechnology (ROCO:3118) Overvalued in 2026?
Based on GuruFocus' analysis, Level Biotechnology stock appears to be undervalued.
The current stock price of NT$31.75 is trading 10.7% below its estimated GF Value™ of NT$35.57.
GuruFocus considers Level Biotechnology to be Modestly Undervalued.
Key valuation signals for ROCO:3118:
EBITDA Margin %: 15.26% (near median its 10-year median of 15.23)
GF Value™: NT$35.57 vs. price of NT$31.75 (10.7% below fair value)
No single metric tells the full story. See the ROCO:3118 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Level Biotechnology Inc is a Taiwan-based company engaged in the sales of biomedical products and providing preclinical testing services. The company has three reportable segments: Department A and B, Department C, and Department D. Department A and Department B sell the cell culture consumables and the antibody reagents, Department C sells the instruments and equipment, and Department D provides CRO services. The majority of revenue is derived from the Department A and B.
76GF Score
Get the complete analysis for ROCO:3118
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:3118 has been successfully added to your 
